ArticleKidney international reports2021

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD.

Hiddo J L Heerspink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.